Sector News

Reuters: Shire closer to deal to buy Baxalta

December 24, 2015
Life sciences

(Reuters) – Drug maker Shire Plc (SHP.L) has made a new acquisition offer for peer Baxalta International Inc (BXLT.N) that is roughly in line with the latter’s valuation expectations, making a deal in the coming weeks likely, people familiar with the matter said.

An agreement would successfully end Dublin-based Shire’s five-month pursuit of Bannockburn, Illinois-based Baxalta and create one of the world’s leading specialists in rare diseases.

Baxalta’s board rejected an all-stock offer from Shire in August, saying it had significantly undervalued the company.

While the exact terms of the deal could not be learned, Shire has now added enough cash to its previous all-stock offer for talks to advance, the people said. Baxalta would be valued in excess of $30 billion in any deal, one of the people added.

Baxalta shares were up 4.4 percent at $39.74 in afternoon trading in New York. American depository shares of Shire were trading down 0.4 percent at $194.40.

The sources asked not to be identified because the negotiations are confidential. Baxalta and Shire spokespeople offered no comment.

The challenging deal talks with Baxalta came after Shire pursued other deals in the rare diseases sector. Shire announced on Nov. 2 it was buying Dyax, which manufactures treatments for a rare genetic disease, for $5.9 billion.

A combination of Shire and Baxalta would add to the more than $600 billion in healthcare merger deals this year, which has been the busiest in the history of healthcare deal making.

Baxalta develops biotech treatments for rare blood conditions, cancers and immune system disorders. It was spun off was spun off from Baxter International Inc (BAX.N) in July.

By Carl O’Donnell and Pamela Barbaglia

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend